<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962207</url>
  </required_header>
  <id_info>
    <org_study_id>MENACWY-TT-100</org_study_id>
    <secondary_id>2013-001549-15</secondary_id>
    <secondary_id>C0921004</secondary_id>
    <secondary_id>200171</secondary_id>
    <nct_id>NCT01962207</nct_id>
  </id_info>
  <brief_title>The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination</brief_title>
  <official_title>A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF THE MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGITEC(REGISTERED) VACCINE OR ONE DOSE OF THE MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 1-10 YEAR OLD SUBJECTS WITH MENACWY-TT, MENINGITEC(REGISTERED) OR MENCEVAX(REGISTERED) ACWY.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term antibody persistence 6, 7, 8, 9 and 10
      years after receiving a primary vaccination of meningococcal conjugate vaccine MenACWY-TT
      versus Meningitec™ or Mencevax™ ACWY, and the safety and immunogenicity of a booster dose of
      MenACWY-TT administered 10 years after the primary vaccination. All subjects received a
      primary vaccination at 1 to 10 years of age in study 108658 (NCT00427908). No new subjects
      will be enrolled in this booster study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to evaluate the antibody persistence post primary vaccination with active
      control, safety and immunogenicity of a booster dose uncontrolled post primary vaccination
      during different phases:

      Persistence phase: Long-term persistence 6, 7, 8, 9 and 10 years after primary vaccination
      with MenACWY-TT or Meningitec or Mencevax ACWY, in study MenACWY-TT-027.

      Booster phase: One month post booster vaccination with MenACWY-TT vaccine ten years after
      primary vaccination.

      The subjects in this study will be allocated to the same groups as in the vaccination study
      MenACWY-TT-027 (NCT00427908).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination</measure>
    <time_frame>6 years after primary vaccination (Year 1 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination</measure>
    <time_frame>7 years after primary vaccination (Year 2 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination</measure>
    <time_frame>8 years after primary vaccination (Year 3 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination</measure>
    <time_frame>9 years after primary vaccination (Year 4 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination</measure>
    <time_frame>10 years after primary vaccination (Year 4 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination</measure>
    <time_frame>6 Years after primary vaccination (Year 1 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination</measure>
    <time_frame>7 years after primary vaccination (Year 2 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination</measure>
    <time_frame>8 years after primary vaccination (Year 3 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination</measure>
    <time_frame>9 years after primary vaccination (Year 4 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination</measure>
    <time_frame>10 years after primary vaccination (Year 5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;=1:4 and &gt;=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination</measure>
    <time_frame>6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination</measure>
    <time_frame>6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With rSBA Titers &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination</measure>
    <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination</measure>
    <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination</measure>
    <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: rSBA antibody titer &gt;= 1:32 one month after vaccination, and at least 4-fold increase in rSBA titers one month after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With hSBA Titers &gt;=1:4 and &gt;=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination</measure>
    <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination</measure>
    <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination</measure>
    <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY. hSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: hSBA antibody titer &gt;= 1:8 one month after vaccination, and at least 4-fold increase in hSBA titers one month after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy</measure>
    <time_frame>Through 5 years (6, 7, 8, 9 and 10 years post primary vaccination)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs related to &quot;lack of vaccine efficacy&quot; were as judged by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination</measure>
    <time_frame>Up to 4 days post booster vaccination</time_frame>
    <description>Solicited general events: fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea and/or abdominal pain, headache (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe/prevented normal activity) and fever (&gt;=37.5°C for oral/axillary/tympanic route, &gt;=38.0°C for rectal route). Solicited local events: pain (0=none, 1=mild, not interfered/prevented normal activity, 2=moderate, painful when limb moved/interfered with normal activity, 3=severe, significant pain at rest/prevented normal activity), redness and swelling at injection site (record greatest surface diameter in millimeter (mm) as 0 to &lt;=20 mm, &gt;20 to &lt;=50 mm, &gt;50 mm). Participants may be represented in more than 1 category. Only categories with at least 1 participant reported. 'Medical advice' signifies medical advice received to resolve any event. 'Related'=relationship to study vaccine assessed by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination</measure>
    <time_frame>Up to 31 days post booster vaccination</time_frame>
    <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination</measure>
    <time_frame>Up to 6 months post booster vaccination</time_frame>
    <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination</measure>
    <time_frame>Up to 6 months post booster vaccination</time_frame>
    <description>New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>ACWY&lt;2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACWY≥2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenCCRM Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenPS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal vaccine GSK134612</intervention_name>
    <description>One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm</description>
    <arm_group_label>ACWY&lt;2 Group</arm_group_label>
    <arm_group_label>ACWY≥2 Group</arm_group_label>
    <arm_group_label>MenCCRM Group</arm_group_label>
    <arm_group_label>MenPS Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects and/or subjects' parent(s)/Legally Acceptable Representative(s) (LARs) who,
             in the opinion of the investigator, can and will comply with the requirements of the
             protocol.

          -  A male or female who has received a primary vaccination with the MenACWY-TT,
             Meningitec or Mencevax ACWY vaccines in study MenACWY-TT-027 (NCT00427908).

          -  In alignment with local laws and regulations, written informed consent obtained from
             parents/LAR(s) of the subject and written informed assent obtained from the subject if
             the subject is less than 15 years of age, or written informed consent obtained from
             the subject if the subject has achieved the 15th birthday. The subjects ≥15 years of
             age at the time of enrollment will sign the informed consent form, even if the parent/
             LAR previously signed the ICF before the subject reached the legal age of consent.

          -  Healthy subjects as established by medical history and history-directed physical
             examination before entering into the study.

        All subjects must satisfy the following additional criteria prior to entry of the booster
        phase:

          -  Female subjects of non-childbearing potential may be enrolled in the study.

               -  Non-childbearing potential is defined as pre-menarche, hysterectomy or bilateral
                  ovariectomy.

          -  Male subjects able to father children and female subjects of childbearing potential
             (including females who have had tubal ligation) and at risk of pregnancy may be
             enrolled in the study, if the subject:

               -  has practiced adequate contraception for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination (for females only), and

               -  has agreed to continue adequate contraception during the entire treatment period
                  and for 2 months after completion of the vaccination.

        Exclusion Criteria:

          -  Child in care.

          -  Previous vaccination with meningococcal polysaccharide or conjugate vaccine outside of
             study MenACWY-TT-027.

        Note: Subjects who were revaccinated with a monovalent MenC conjugate vaccine because of
        suboptimal response during the persistence phase of the MenACWY-TT-027 study (i.e.
        MenACWY-TT-028, -029, -030, -031 and -032) are allowed to participate as they will be
        followed for the persistence of MenA, MenW-135 and MenY.

          -  History of meningococcal disease due to serogroup A, C, W-135 or Y.

          -  Previous vaccination with meningococcal B vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital
             or secondary), including Human Immunodeficiency Virus (HIV) infection, based on
             medical history and physical examination (no laboratory testing required).

          -  Family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or serious chronic illness.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Subjects who withdrew consent to be contacted for follow-up studies.

        Additional exclusion criteria for booster phase at Month 126 study entry (to be checked at
        Month 126) for all subjects:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine within 30 days preceding the booster dose of study vaccine, or planned
             use during the follow-up period.

          -  Administration of a vaccine not foreseen by the study protocol in the period starting
             30 days before the booster dose of study vaccine or planned administration within 30
             days after vaccination, with the exception of a licensed inactivated influenza
             vaccine.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the booster vaccine dose . Inhaled and topical steroids are
             allowed.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the booster vaccination or planned administration during the follow-up
             period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational vaccine/product .

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccines.

          -  History of any neurological disorders or seizures, including Guillain-Barré syndrome
             (GBS). History of a simple, single febrile seizure is permitted.

          -  Acute disease and/or fever at the time of vaccination.

               -  Fever is defined as temperature ≥ 37.5°C for oral, axillary, tympanic, or ≥38.0°C
                  for rectal route. The preferred route for recording temperature in this study
                  will be oral.

               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
                  infection) without fever may, be enrolled at the discretion of the investigator.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  Male subjects able to father children who are planning to discontinue contraceptive
             precautions.

          -  Subjects who are investigational site staff members directly involved in the conduct
             of the study and their family members, site staff members otherwise supervised by the
             investigator, or subjects who are Pfizer employees directly involved in the conduct of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Helsinki Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki East Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaa Vaccine Research Clinic</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto/ Oulun rokotetutkimusklinikka</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto/ Porin rokotetutkimusklinikka</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto/ Turun rokotetutkimusklinikka</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto/ Ita-Vantaan rokotetutkimusklinikka</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=MENACWY-TT-100&amp;StudyName=A%20Phase%20Iiib%2C%20Open%2C%20Multi-center%20Study%20To%20Evaluate%20The%20Long-term%20Antibody%20Persistence%20At%206%2C%207%2C%208%2C%209%20And%2010%20Years%20After%20The%20Administration%20Of%20One%20Dose%20Of%20The%20Meningococcal%20Conjugate%20Vaccine%20Menacwy-tt%20Versus%20One%20Dose%20Of%20Meningitec%28registered%29%20Vaccine%20Or%20One%20Dose%20Of%20The%20Meningococcal%20Polysaccharide%20Vaccine%20Mencevax%28registered%29%20Acwy%2C%20And%20To%20Evaluate%20The%20Safety%20And%20Immunogenicity%20Of%20A%20Booster%20Dose%20Of%20Menacwy-tt%20Vaccine%20Administered%2010%20Years%20After%20Primary%20Vaccination%20Of%201-10%20Year%20Old%20Subjects%20With%20Menacwy-tt%2C%20Meningitec%28registered%29%20Or%20Mencevax%28registered%29%20Acwy.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <results_first_submitted>March 4, 2019</results_first_submitted>
  <results_first_submitted_qc>March 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2019</results_first_posted>
  <disposition_first_submitted>October 30, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>October 30, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 2, 2018</disposition_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>10 years Meningitec</keyword>
  <keyword>Safety</keyword>
  <keyword>booster response</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Adults</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Mencevax ACWY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01962207/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01962207/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In this study, participants from the study MENACWY-TT-027 [NCT00427908] were followed up for assessment of persistence of immune response and safety. And those who consented received booster vaccination and were followed up for another 6 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
        <group group_id="P2">
          <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
        <group group_id="P3">
          <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
        <group group_id="P4">
          <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Persistence Phase (5 Years)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="115"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed at least 1 persistence visit</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Booster Phase (6 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67">Eligible participants from persistence phase who provided consent to get enrolled in booster phase.</participants>
                <participants group_id="P2" count="16">Eligible participants from persistence phase who provided consent to get enrolled in booster phase.</participants>
                <participants group_id="P3" count="77">Eligible participants from persistence phase who provided consent to get enrolled in booster phase.</participants>
                <participants group_id="P4" count="21">Eligible participants from persistence phase who provided consent to get enrolled in booster phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population included all the participants enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
        <group group_id="B2">
          <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
        <group group_id="B3">
          <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
        <group group_id="B4">
          <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
          <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="115"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="243"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="0.7"/>
                    <measurement group_id="B2" value="8.2" spread="0.7"/>
                    <measurement group_id="B3" value="12.5" spread="2.6"/>
                    <measurement group_id="B4" value="12.1" spread="2.9"/>
                    <measurement group_id="B5" value="10.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White - Arabic/North African heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Caucasian/European heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination</title>
        <description>Serogroups included Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY).</description>
        <time_frame>6 years after primary vaccination (Year 1 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec, or Mencevax ACWY during study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. Here, “Overall Number of Participants Analyzed” (N) signifies number of participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination</title>
          <description>Serogroups included Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY).</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec, or Mencevax ACWY during study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. Here, “Overall Number of Participants Analyzed” (N) signifies number of participants evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" lower_limit="37.8" upper_limit="65.7"/>
                    <measurement group_id="O2" value="18.8" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O3" value="79.6" lower_limit="70.3" upper_limit="87.1"/>
                    <measurement group_id="O4" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="64.4" upper_limit="88.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="47.6" upper_limit="92.7"/>
                    <measurement group_id="O3" value="82.7" lower_limit="73.7" upper_limit="89.6"/>
                    <measurement group_id="O4" value="79.2" lower_limit="57.8" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="21.1" upper_limit="47.5"/>
                    <measurement group_id="O2" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                    <measurement group_id="O3" value="73.5" lower_limit="63.6" upper_limit="81.9"/>
                    <measurement group_id="O4" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" lower_limit="25.9" upper_limit="53.1"/>
                    <measurement group_id="O2" value="37.5" lower_limit="15.2" upper_limit="64.6"/>
                    <measurement group_id="O3" value="71.4" lower_limit="61.4" upper_limit="80.1"/>
                    <measurement group_id="O4" value="20.8" lower_limit="7.1" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="7.9" upper_limit="29.3"/>
                    <measurement group_id="O2" value="6.3" lower_limit="0.2" upper_limit="30.2"/>
                    <measurement group_id="O3" value="55.1" lower_limit="44.7" upper_limit="65.2"/>
                    <measurement group_id="O4" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" lower_limit="56.4" upper_limit="82.0"/>
                    <measurement group_id="O2" value="56.3" lower_limit="29.9" upper_limit="80.2"/>
                    <measurement group_id="O3" value="68.4" lower_limit="58.2" upper_limit="77.4"/>
                    <measurement group_id="O4" value="62.5" lower_limit="40.6" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="18.0" upper_limit="43.6"/>
                    <measurement group_id="O2" value="6.3" lower_limit="0.2" upper_limit="30.2"/>
                    <measurement group_id="O3" value="73.5" lower_limit="63.6" upper_limit="81.9"/>
                    <measurement group_id="O4" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="21.1" upper_limit="47.5"/>
                    <measurement group_id="O2" value="31.3" lower_limit="11.0" upper_limit="58.7"/>
                    <measurement group_id="O3" value="65.3" lower_limit="55.0" upper_limit="74.6"/>
                    <measurement group_id="O4" value="20.8" lower_limit="7.1" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>7 years after primary vaccination (Year 2 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" lower_limit="44.9" upper_limit="70.9"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="74.0" lower_limit="64.5" upper_limit="82.1"/>
                    <measurement group_id="O4" value="18.5" lower_limit="6.3" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="101"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="65.8" upper_limit="87.9"/>
                    <measurement group_id="O2" value="71.4" lower_limit="47.8" upper_limit="88.7"/>
                    <measurement group_id="O3" value="84.2" lower_limit="75.6" upper_limit="90.7"/>
                    <measurement group_id="O4" value="81.5" lower_limit="61.9" upper_limit="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="16.1" upper_limit="39.7"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="73.5" lower_limit="63.9" upper_limit="81.8"/>
                    <measurement group_id="O4" value="11.1" lower_limit="2.4" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="23.1" upper_limit="48.4"/>
                    <measurement group_id="O2" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O3" value="75.5" lower_limit="66.0" upper_limit="83.5"/>
                    <measurement group_id="O4" value="14.8" lower_limit="4.2" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA: &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="12.1" upper_limit="34.2"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="44.2" lower_limit="34.5" upper_limit="54.3"/>
                    <measurement group_id="O4" value="11.1" lower_limit="2.4" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="101"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" lower_limit="48.2" upper_limit="73.9"/>
                    <measurement group_id="O2" value="52.4" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O3" value="61.4" lower_limit="51.2" upper_limit="70.9"/>
                    <measurement group_id="O4" value="66.7" lower_limit="46.0" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="13.4" upper_limit="36.0"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="69.6" lower_limit="59.7" upper_limit="78.3"/>
                    <measurement group_id="O4" value="7.4" lower_limit="0.9" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="21.7" upper_limit="46.7"/>
                    <measurement group_id="O2" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                    <measurement group_id="O3" value="69.6" lower_limit="59.7" upper_limit="78.3"/>
                    <measurement group_id="O4" value="14.8" lower_limit="4.2" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>8 years after primary vaccination (Year 3 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="35.1" upper_limit="60.5"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="70.0" lower_limit="60.0" upper_limit="78.8"/>
                    <measurement group_id="O4" value="24.0" lower_limit="9.4" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="66.5" upper_limit="87.7"/>
                    <measurement group_id="O2" value="77.3" lower_limit="54.6" upper_limit="92.2"/>
                    <measurement group_id="O3" value="85.0" lower_limit="76.5" upper_limit="91.4"/>
                    <measurement group_id="O4" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="18.6" upper_limit="41.8"/>
                    <measurement group_id="O2" value="13.6" lower_limit="2.9" upper_limit="34.9"/>
                    <measurement group_id="O3" value="76.0" lower_limit="66.4" upper_limit="84.0"/>
                    <measurement group_id="O4" value="20.0" lower_limit="6.8" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="28.0" upper_limit="52.9"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="79.0" lower_limit="69.7" upper_limit="86.5"/>
                    <measurement group_id="O4" value="24.0" lower_limit="9.4" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="13.5" upper_limit="35.2"/>
                    <measurement group_id="O2" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O3" value="45.0" lower_limit="35.0" upper_limit="55.3"/>
                    <measurement group_id="O4" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="51.8" upper_limit="76.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="28.2" upper_limit="71.8"/>
                    <measurement group_id="O3" value="61.0" lower_limit="50.7" upper_limit="70.6"/>
                    <measurement group_id="O4" value="64.0" lower_limit="42.5" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="17.3" upper_limit="40.2"/>
                    <measurement group_id="O2" value="9.1" lower_limit="1.1" upper_limit="29.2"/>
                    <measurement group_id="O3" value="76.0" lower_limit="66.4" upper_limit="84.0"/>
                    <measurement group_id="O4" value="20.0" lower_limit="6.8" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="26.7" upper_limit="51.4"/>
                    <measurement group_id="O2" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O3" value="73.0" lower_limit="63.2" upper_limit="81.4"/>
                    <measurement group_id="O4" value="20.0" lower_limit="6.8" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>9 years after primary vaccination (Year 4 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="54.3" upper_limit="78.4"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O3" value="79.6" lower_limit="69.9" upper_limit="87.2"/>
                    <measurement group_id="O4" value="24.0" lower_limit="9.4" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="69.5" upper_limit="89.9"/>
                    <measurement group_id="O2" value="85.7" lower_limit="63.7" upper_limit="97.0"/>
                    <measurement group_id="O3" value="86.0" lower_limit="77.3" upper_limit="92.3"/>
                    <measurement group_id="O4" value="84.0" lower_limit="63.9" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="21.6" upper_limit="45.7"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="76.1" lower_limit="66.1" upper_limit="84.4"/>
                    <measurement group_id="O4" value="16.0" lower_limit="4.5" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="29.9" upper_limit="55.2"/>
                    <measurement group_id="O2" value="47.6" lower_limit="25.7" upper_limit="70.2"/>
                    <measurement group_id="O3" value="66.7" lower_limit="56.1" upper_limit="76.1"/>
                    <measurement group_id="O4" value="20.0" lower_limit="6.8" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="20.2" upper_limit="44.1"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O3" value="57.0" lower_limit="46.3" upper_limit="67.2"/>
                    <measurement group_id="O4" value="16.0" lower_limit="4.5" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" lower_limit="52.7" upper_limit="77.1"/>
                    <measurement group_id="O2" value="57.1" lower_limit="34.0" upper_limit="78.2"/>
                    <measurement group_id="O3" value="64.5" lower_limit="53.9" upper_limit="74.2"/>
                    <measurement group_id="O4" value="68.0" lower_limit="46.5" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="16.3" upper_limit="39.1"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                    <measurement group_id="O3" value="71.7" lower_limit="61.4" upper_limit="80.6"/>
                    <measurement group_id="O4" value="16.0" lower_limit="4.5" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="22.9" upper_limit="47.3"/>
                    <measurement group_id="O2" value="38.1" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O3" value="58.1" lower_limit="47.4" upper_limit="68.2"/>
                    <measurement group_id="O4" value="16.0" lower_limit="4.5" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>10 years after primary vaccination (Year 4 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Percentage of Participants With rSBA Titers &gt;= 1:8 and &gt;=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" lower_limit="52.7" upper_limit="77.1"/>
                    <measurement group_id="O2" value="17.6" lower_limit="3.8" upper_limit="43.4"/>
                    <measurement group_id="O3" value="88.9" lower_limit="80.0" upper_limit="94.8"/>
                    <measurement group_id="O4" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="71.3" upper_limit="91.1"/>
                    <measurement group_id="O2" value="88.2" lower_limit="63.6" upper_limit="98.5"/>
                    <measurement group_id="O3" value="84.1" lower_limit="74.4" upper_limit="91.3"/>
                    <measurement group_id="O4" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="20.2" upper_limit="44.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="19.5"/>
                    <measurement group_id="O3" value="67.1" lower_limit="55.8" upper_limit="77.1"/>
                    <measurement group_id="O4" value="23.8" lower_limit="8.2" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="31.4" upper_limit="56.7"/>
                    <measurement group_id="O2" value="35.3" lower_limit="14.2" upper_limit="61.7"/>
                    <measurement group_id="O3" value="65.9" lower_limit="54.6" upper_limit="76.0"/>
                    <measurement group_id="O4" value="23.8" lower_limit="8.2" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="16.3" upper_limit="39.1"/>
                    <measurement group_id="O2" value="5.9" lower_limit="0.1" upper_limit="28.7"/>
                    <measurement group_id="O3" value="49.4" lower_limit="38.1" upper_limit="60.7"/>
                    <measurement group_id="O4" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" lower_limit="51.1" upper_limit="75.7"/>
                    <measurement group_id="O2" value="58.8" lower_limit="32.9" upper_limit="81.6"/>
                    <measurement group_id="O3" value="65.9" lower_limit="54.6" upper_limit="76.0"/>
                    <measurement group_id="O4" value="66.7" lower_limit="43.0" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="17.6" upper_limit="40.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="19.5"/>
                    <measurement group_id="O3" value="65.9" lower_limit="54.6" upper_limit="76.0"/>
                    <measurement group_id="O4" value="23.8" lower_limit="8.2" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY &gt;=1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" lower_limit="24.3" upper_limit="48.9"/>
                    <measurement group_id="O2" value="29.4" lower_limit="10.3" upper_limit="56.0"/>
                    <measurement group_id="O3" value="59.8" lower_limit="48.3" upper_limit="70.4"/>
                    <measurement group_id="O4" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>6 Years after primary vaccination (Year 1 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="9.8" upper_limit="26.1"/>
                    <measurement group_id="O2" value="5.9" lower_limit="3.1" upper_limit="11.3"/>
                    <measurement group_id="O3" value="107.3" lower_limit="66.0" upper_limit="174.3"/>
                    <measurement group_id="O4" value="5.8" lower_limit="3.5" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.3" lower_limit="84.7" upper_limit="307.1"/>
                    <measurement group_id="O2" value="103.1" lower_limit="31.9" upper_limit="333.3"/>
                    <measurement group_id="O3" value="192.9" lower_limit="121.0" upper_limit="307.5"/>
                    <measurement group_id="O4" value="98.7" lower_limit="42.2" upper_limit="230.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="9.8" upper_limit="32.9"/>
                    <measurement group_id="O2" value="6.2" lower_limit="3.1" upper_limit="12.3"/>
                    <measurement group_id="O3" value="265.2" lower_limit="154.9" upper_limit="454.1"/>
                    <measurement group_id="O4" value="7.6" lower_limit="3.7" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="11.5" upper_limit="40.1"/>
                    <measurement group_id="O2" value="21.7" lower_limit="5.9" upper_limit="79.0"/>
                    <measurement group_id="O3" value="136.4" lower_limit="82.6" upper_limit="225.3"/>
                    <measurement group_id="O4" value="11.6" lower_limit="4.7" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>7 years after primary vaccination (Year 2 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="12.1" upper_limit="34.4"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.3" upper_limit="11.4"/>
                    <measurement group_id="O3" value="65.3" lower_limit="40.5" upper_limit="105.4"/>
                    <measurement group_id="O4" value="7.4" lower_limit="4.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="101"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.0" lower_limit="58.0" upper_limit="186.3"/>
                    <measurement group_id="O2" value="54.3" lower_limit="18.5" upper_limit="158.9"/>
                    <measurement group_id="O3" value="139.0" lower_limit="87.8" upper_limit="220.0"/>
                    <measurement group_id="O4" value="101.6" lower_limit="42.1" upper_limit="245.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="7.6" upper_limit="22.3"/>
                    <measurement group_id="O2" value="6.8" lower_limit="3.0" upper_limit="15.3"/>
                    <measurement group_id="O3" value="206.0" lower_limit="120.9" upper_limit="350.9"/>
                    <measurement group_id="O4" value="6.3" lower_limit="3.7" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" lower_limit="11.0" upper_limit="36.1"/>
                    <measurement group_id="O2" value="18.3" lower_limit="5.8" upper_limit="57.6"/>
                    <measurement group_id="O3" value="152.7" lower_limit="96.1" upper_limit="242.6"/>
                    <measurement group_id="O4" value="8.2" lower_limit="4.1" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>8 years after primary vaccination (Year 3 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="9.8" upper_limit="25.6"/>
                    <measurement group_id="O2" value="4.8" lower_limit="3.3" upper_limit="7.2"/>
                    <measurement group_id="O3" value="51.3" lower_limit="31.5" upper_limit="83.4"/>
                    <measurement group_id="O4" value="7.8" lower_limit="4.2" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.2" lower_limit="65.9" upper_limit="184.3"/>
                    <measurement group_id="O2" value="64.0" lower_limit="26.0" upper_limit="157.4"/>
                    <measurement group_id="O3" value="140.1" lower_limit="91.3" upper_limit="214.9"/>
                    <measurement group_id="O4" value="121.1" lower_limit="52.2" upper_limit="281.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="9.0" upper_limit="26.3"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.3" upper_limit="12.4"/>
                    <measurement group_id="O3" value="252.5" lower_limit="154.3" upper_limit="413.2"/>
                    <measurement group_id="O4" value="11.8" lower_limit="4.7" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="14.4" upper_limit="47.5"/>
                    <measurement group_id="O2" value="33.0" lower_limit="9.8" upper_limit="111.0"/>
                    <measurement group_id="O3" value="181.0" lower_limit="115.0" upper_limit="284.9"/>
                    <measurement group_id="O4" value="10.9" lower_limit="4.8" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>9 years after primary vaccination (Year 4 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" lower_limit="16.5" upper_limit="48.9"/>
                    <measurement group_id="O2" value="5.2" lower_limit="3.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="118.8" lower_limit="71.1" upper_limit="198.6"/>
                    <measurement group_id="O4" value="10.9" lower_limit="4.5" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.0" lower_limit="92.3" upper_limit="298.7"/>
                    <measurement group_id="O2" value="92.0" lower_limit="32.7" upper_limit="259.1"/>
                    <measurement group_id="O3" value="176.4" lower_limit="106.8" upper_limit="291.3"/>
                    <measurement group_id="O4" value="164.3" lower_limit="66.5" upper_limit="405.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="9.7" upper_limit="30.8"/>
                    <measurement group_id="O2" value="6.6" lower_limit="3.2" upper_limit="13.6"/>
                    <measurement group_id="O3" value="274.0" lower_limit="155.8" upper_limit="481.7"/>
                    <measurement group_id="O4" value="9.7" lower_limit="4.0" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="13.0" upper_limit="41.2"/>
                    <measurement group_id="O2" value="32.0" lower_limit="10.6" upper_limit="96.3"/>
                    <measurement group_id="O3" value="106.2" lower_limit="61.5" upper_limit="183.4"/>
                    <measurement group_id="O4" value="10.0" lower_limit="4.4" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>10 years after primary vaccination (Year 5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="16.8" upper_limit="51.3"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.2" upper_limit="10.6"/>
                    <measurement group_id="O3" value="106.0" lower_limit="63.7" upper_limit="176.4"/>
                    <measurement group_id="O4" value="9.1" lower_limit="4.0" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.2" lower_limit="74.5" upper_limit="234.6"/>
                    <measurement group_id="O2" value="81.7" lower_limit="29.2" upper_limit="229.2"/>
                    <measurement group_id="O3" value="175.0" lower_limit="104.7" upper_limit="292.4"/>
                    <measurement group_id="O4" value="105.0" lower_limit="37.2" upper_limit="296.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="9.5" upper_limit="29.3"/>
                    <measurement group_id="O2" value="4.0" lower_limit="NA" upper_limit="NA">The confidence interval was not estimable due to the lack of variability of antibody titer.</measurement>
                    <measurement group_id="O3" value="187.2" lower_limit="101.0" upper_limit="347.1"/>
                    <measurement group_id="O4" value="14.0" lower_limit="4.8" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="14.0" upper_limit="47.3"/>
                    <measurement group_id="O2" value="22.2" lower_limit="5.8" upper_limit="84.2"/>
                    <measurement group_id="O3" value="90.5" lower_limit="51.5" upper_limit="159.2"/>
                    <measurement group_id="O4" value="12.7" lower_limit="4.2" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;=1:4 and &gt;=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers &gt;=1:4 and &gt;=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 of study MENACWY-TT-100: hSBA-MenA &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="20.5" upper_limit="49.9"/>
                    <measurement group_id="O2" value="28.6" lower_limit="8.4" upper_limit="58.1"/>
                    <measurement group_id="O3" value="42.2" lower_limit="31.9" upper_limit="53.1"/>
                    <measurement group_id="O4" value="42.9" lower_limit="21.8" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenA &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="16.1" upper_limit="39.7"/>
                    <measurement group_id="O2" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O3" value="26.3" lower_limit="17.9" upper_limit="36.1"/>
                    <measurement group_id="O4" value="26.9" lower_limit="11.6" upper_limit="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenA &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="21.6" upper_limit="45.7"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="28.9" lower_limit="20.1" upper_limit="39.0"/>
                    <measurement group_id="O4" value="40.0" lower_limit="21.1" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenA &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" lower_limit="27.6" upper_limit="52.8"/>
                    <measurement group_id="O2" value="30.0" lower_limit="11.9" upper_limit="54.3"/>
                    <measurement group_id="O3" value="43.0" lower_limit="32.4" upper_limit="54.2"/>
                    <measurement group_id="O4" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenA &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="19.9" upper_limit="44.3"/>
                    <measurement group_id="O2" value="25.0" lower_limit="7.3" upper_limit="52.4"/>
                    <measurement group_id="O3" value="34.8" lower_limit="23.7" upper_limit="47.2"/>
                    <measurement group_id="O4" value="33.3" lower_limit="14.6" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-10: hSBA-MenC &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="81.8" upper_limit="97.9"/>
                    <measurement group_id="O2" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="93.8" lower_limit="87.0" upper_limit="97.7"/>
                    <measurement group_id="O4" value="100.0" lower_limit="85.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenC &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="79.2" upper_limit="96.2"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="88.5" lower_limit="80.4" upper_limit="94.1"/>
                    <measurement group_id="O4" value="92.3" lower_limit="74.9" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenC &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="82.7" upper_limit="97.4"/>
                    <measurement group_id="O2" value="95.5" lower_limit="77.2" upper_limit="99.9"/>
                    <measurement group_id="O3" value="89.6" lower_limit="81.7" upper_limit="94.9"/>
                    <measurement group_id="O4" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenC &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="80.4" upper_limit="96.4"/>
                    <measurement group_id="O2" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O3" value="86.7" lower_limit="77.9" upper_limit="92.9"/>
                    <measurement group_id="O4" value="91.7" lower_limit="73.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenC &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="82.2" upper_limit="97.3"/>
                    <measurement group_id="O2" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="91.1" lower_limit="82.6" upper_limit="96.4"/>
                    <measurement group_id="O4" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-10: hSBA-MenW-135&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="55.1" upper_limit="82.7"/>
                    <measurement group_id="O2" value="13.3" lower_limit="1.7" upper_limit="40.5"/>
                    <measurement group_id="O3" value="81.5" lower_limit="72.1" upper_limit="88.9"/>
                    <measurement group_id="O4" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenW-135&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" lower_limit="46.6" upper_limit="73.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O3" value="79.6" lower_limit="70.3" upper_limit="87.1"/>
                    <measurement group_id="O4" value="18.5" lower_limit="6.3" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenW-135&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="94"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="27.1" upper_limit="52.1"/>
                    <measurement group_id="O2" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O3" value="56.4" lower_limit="45.8" upper_limit="66.6"/>
                    <measurement group_id="O4" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenW-135&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="31.7" upper_limit="58.5"/>
                    <measurement group_id="O2" value="18.8" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O3" value="68.4" lower_limit="56.9" upper_limit="78.4"/>
                    <measurement group_id="O4" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenW-135&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="30.9" upper_limit="58.6"/>
                    <measurement group_id="O2" value="21.4" lower_limit="4.7" upper_limit="50.8"/>
                    <measurement group_id="O3" value="61.2" lower_limit="48.5" upper_limit="72.9"/>
                    <measurement group_id="O4" value="26.3" lower_limit="9.1" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-10: hSBA-MenY&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="18.1" upper_limit="48.1"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                    <measurement group_id="O3" value="65.2" lower_limit="54.3" upper_limit="75.0"/>
                    <measurement group_id="O4" value="25.0" lower_limit="9.8" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenY&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="38.0" upper_limit="65.3"/>
                    <measurement group_id="O2" value="33.3" lower_limit="14.6" upper_limit="57.0"/>
                    <measurement group_id="O3" value="75.0" lower_limit="65.3" upper_limit="83.1"/>
                    <measurement group_id="O4" value="40.7" lower_limit="22.4" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenY&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="37.9" upper_limit="63.6"/>
                    <measurement group_id="O2" value="38.1" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O3" value="72.0" lower_limit="61.8" upper_limit="80.9"/>
                    <measurement group_id="O4" value="34.8" lower_limit="16.4" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenY&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="21.3" upper_limit="46.0"/>
                    <measurement group_id="O2" value="26.3" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O3" value="67.9" lower_limit="56.8" upper_limit="77.6"/>
                    <measurement group_id="O4" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenY&gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" lower_limit="28.6" upper_limit="55.1"/>
                    <measurement group_id="O2" value="40.0" lower_limit="16.3" upper_limit="67.7"/>
                    <measurement group_id="O3" value="72.6" lower_limit="60.9" upper_limit="82.4"/>
                    <measurement group_id="O4" value="44.4" lower_limit="21.5" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-10: hSBA-MenA&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="18.6" upper_limit="47.6"/>
                    <measurement group_id="O2" value="28.6" lower_limit="8.4" upper_limit="58.1"/>
                    <measurement group_id="O3" value="41.1" lower_limit="30.8" upper_limit="52.0"/>
                    <measurement group_id="O4" value="33.3" lower_limit="14.6" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenA&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="14.7" upper_limit="37.9"/>
                    <measurement group_id="O2" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                    <measurement group_id="O3" value="26.3" lower_limit="17.9" upper_limit="36.1"/>
                    <measurement group_id="O4" value="23.1" lower_limit="9.0" upper_limit="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenA&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="21.6" upper_limit="45.7"/>
                    <measurement group_id="O2" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                    <measurement group_id="O3" value="28.9" lower_limit="20.1" upper_limit="39.0"/>
                    <measurement group_id="O4" value="36.0" lower_limit="18.0" upper_limit="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenA&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="19.2" upper_limit="43.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O3" value="43.0" lower_limit="32.4" upper_limit="54.2"/>
                    <measurement group_id="O4" value="26.1" lower_limit="10.2" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenA&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" lower_limit="15.8" upper_limit="39.1"/>
                    <measurement group_id="O2" value="18.8" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O3" value="33.3" lower_limit="22.4" upper_limit="45.7"/>
                    <measurement group_id="O4" value="28.6" lower_limit="11.3" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-10: hSBA-MenC&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="81.8" upper_limit="97.9"/>
                    <measurement group_id="O2" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="93.8" lower_limit="87.0" upper_limit="97.7"/>
                    <measurement group_id="O4" value="100.0" lower_limit="85.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenC&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="79.2" upper_limit="96.2"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="88.5" lower_limit="80.4" upper_limit="94.1"/>
                    <measurement group_id="O4" value="92.3" lower_limit="74.9" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenC&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="82.7" upper_limit="97.4"/>
                    <measurement group_id="O2" value="95.5" lower_limit="77.2" upper_limit="99.9"/>
                    <measurement group_id="O3" value="89.6" lower_limit="81.7" upper_limit="94.9"/>
                    <measurement group_id="O4" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenC&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="80.4" upper_limit="96.4"/>
                    <measurement group_id="O2" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                    <measurement group_id="O3" value="85.6" lower_limit="76.6" upper_limit="92.1"/>
                    <measurement group_id="O4" value="91.7" lower_limit="73.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenC&gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="82.2" upper_limit="97.3"/>
                    <measurement group_id="O2" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="91.1" lower_limit="82.6" upper_limit="96.4"/>
                    <measurement group_id="O4" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-10: hSBA-MenW-135 &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="55.1" upper_limit="82.7"/>
                    <measurement group_id="O2" value="13.3" lower_limit="1.7" upper_limit="40.5"/>
                    <measurement group_id="O3" value="81.5" lower_limit="72.1" upper_limit="88.9"/>
                    <measurement group_id="O4" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenW-135 &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" lower_limit="46.6" upper_limit="73.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5.7" upper_limit="43.7"/>
                    <measurement group_id="O3" value="79.6" lower_limit="70.3" upper_limit="87.1"/>
                    <measurement group_id="O4" value="18.5" lower_limit="6.3" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenW-135 &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="94"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="27.1" upper_limit="52.1"/>
                    <measurement group_id="O2" value="19.0" lower_limit="5.4" upper_limit="41.9"/>
                    <measurement group_id="O3" value="56.4" lower_limit="45.8" upper_limit="66.6"/>
                    <measurement group_id="O4" value="12.0" lower_limit="2.5" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenW-135 &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="31.7" upper_limit="58.5"/>
                    <measurement group_id="O2" value="18.8" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O3" value="67.1" lower_limit="55.6" upper_limit="77.3"/>
                    <measurement group_id="O4" value="9.5" lower_limit="1.2" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenW-135 &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="30.9" upper_limit="58.6"/>
                    <measurement group_id="O2" value="21.4" lower_limit="4.7" upper_limit="50.8"/>
                    <measurement group_id="O3" value="61.2" lower_limit="48.5" upper_limit="72.9"/>
                    <measurement group_id="O4" value="26.3" lower_limit="9.1" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-10: hSBA-MenY &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="18.1" upper_limit="48.1"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.2" upper_limit="33.9"/>
                    <measurement group_id="O3" value="65.2" lower_limit="54.3" upper_limit="75.0"/>
                    <measurement group_id="O4" value="25.0" lower_limit="9.8" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-10: hSBA-MenY &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="38.0" upper_limit="65.3"/>
                    <measurement group_id="O2" value="33.3" lower_limit="14.6" upper_limit="57.0"/>
                    <measurement group_id="O3" value="75.0" lower_limit="65.3" upper_limit="83.1"/>
                    <measurement group_id="O4" value="40.7" lower_limit="22.4" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-10: hSBA-MenY &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="37.9" upper_limit="63.6"/>
                    <measurement group_id="O2" value="38.1" lower_limit="18.1" upper_limit="61.6"/>
                    <measurement group_id="O3" value="72.0" lower_limit="61.8" upper_limit="80.9"/>
                    <measurement group_id="O4" value="34.8" lower_limit="16.4" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-10: hSBA-MenY &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="21.3" upper_limit="46.0"/>
                    <measurement group_id="O2" value="26.3" lower_limit="9.1" upper_limit="51.2"/>
                    <measurement group_id="O3" value="67.9" lower_limit="56.8" upper_limit="77.6"/>
                    <measurement group_id="O4" value="27.3" lower_limit="10.7" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-10: hSBA-MenY &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" lower_limit="28.6" upper_limit="55.1"/>
                    <measurement group_id="O2" value="40.0" lower_limit="16.3" upper_limit="67.7"/>
                    <measurement group_id="O3" value="72.6" lower_limit="60.9" upper_limit="82.4"/>
                    <measurement group_id="O4" value="44.4" lower_limit="21.5" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1 of study MENACWY-TT-100: hSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.2" upper_limit="7.1"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.1" upper_limit="5.8"/>
                    <measurement group_id="O3" value="6.5" lower_limit="4.8" upper_limit="8.8"/>
                    <measurement group_id="O4" value="5.9" lower_limit="3.0" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-100: hSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.9" upper_limit="5.2"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.8" upper_limit="4.2"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.4" upper_limit="6.0"/>
                    <measurement group_id="O4" value="4.7" lower_limit="2.4" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-100: hSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="3.5" upper_limit="7.1"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.2" upper_limit="6.1"/>
                    <measurement group_id="O3" value="4.6" lower_limit="3.4" upper_limit="6.0"/>
                    <measurement group_id="O4" value="6.7" lower_limit="3.2" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-100: hSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.5" upper_limit="6.6"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.2" upper_limit="5.2"/>
                    <measurement group_id="O3" value="6.6" lower_limit="4.8" upper_limit="9.0"/>
                    <measurement group_id="O4" value="4.5" lower_limit="2.4" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-100: hSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.1" upper_limit="5.9"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.0" upper_limit="4.8"/>
                    <measurement group_id="O3" value="4.6" lower_limit="3.4" upper_limit="6.2"/>
                    <measurement group_id="O4" value="5.4" lower_limit="2.5" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-100: hSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="542.5" lower_limit="284.8" upper_limit="1033.5"/>
                    <measurement group_id="O2" value="230.0" lower_limit="84.3" upper_limit="628.1"/>
                    <measurement group_id="O3" value="427.2" lower_limit="260.7" upper_limit="700.0"/>
                    <measurement group_id="O4" value="234.8" lower_limit="122.2" upper_limit="451.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-100: hSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.1" lower_limit="191.9" upper_limit="706.0"/>
                    <measurement group_id="O2" value="223.6" lower_limit="105.8" upper_limit="472.7"/>
                    <measurement group_id="O3" value="342.7" lower_limit="200.7" upper_limit="585.4"/>
                    <measurement group_id="O4" value="169.2" lower_limit="67.3" upper_limit="425.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-100: hSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378.2" lower_limit="210.7" upper_limit="679.0"/>
                    <measurement group_id="O2" value="203.4" lower_limit="73.8" upper_limit="560.9"/>
                    <measurement group_id="O3" value="365.5" lower_limit="214.1" upper_limit="624.1"/>
                    <measurement group_id="O4" value="273.8" lower_limit="103.8" upper_limit="722.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-100: hSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319.0" lower_limit="172.7" upper_limit="589.0"/>
                    <measurement group_id="O2" value="217.2" lower_limit="82.8" upper_limit="569.9"/>
                    <measurement group_id="O3" value="190.4" lower_limit="112.1" upper_limit="323.4"/>
                    <measurement group_id="O4" value="125.7" lower_limit="51.2" upper_limit="308.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-100: hSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362.2" lower_limit="207.2" upper_limit="633.4"/>
                    <measurement group_id="O2" value="112.4" lower_limit="41.2" upper_limit="307.0"/>
                    <measurement group_id="O3" value="199.3" lower_limit="118.4" upper_limit="335.7"/>
                    <measurement group_id="O4" value="119.1" lower_limit="50.2" upper_limit="282.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-100: hSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="17.5" upper_limit="57.8"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.6" upper_limit="6.8"/>
                    <measurement group_id="O3" value="62.5" lower_limit="42.0" upper_limit="93.1"/>
                    <measurement group_id="O4" value="7.0" lower_limit="2.9" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-100: hSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="11.6" upper_limit="32.7"/>
                    <measurement group_id="O2" value="4.9" lower_limit="1.9" upper_limit="12.5"/>
                    <measurement group_id="O3" value="50.5" lower_limit="34.5" upper_limit="74.1"/>
                    <measurement group_id="O4" value="4.0" lower_limit="2.1" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-100: hSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="94"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="5.1" upper_limit="12.6"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.9" upper_limit="8.6"/>
                    <measurement group_id="O3" value="20.4" lower_limit="13.0" upper_limit="32.2"/>
                    <measurement group_id="O4" value="3.3" lower_limit="1.8" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-100: hSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5.3" upper_limit="13.5"/>
                    <measurement group_id="O2" value="3.7" lower_limit="1.6" upper_limit="8.4"/>
                    <measurement group_id="O3" value="23.1" lower_limit="14.7" upper_limit="36.1"/>
                    <measurement group_id="O4" value="2.8" lower_limit="1.7" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-100: hSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4.8" upper_limit="11.8"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.7" upper_limit="8.2"/>
                    <measurement group_id="O3" value="17.4" lower_limit="10.8" upper_limit="28.0"/>
                    <measurement group_id="O4" value="4.2" lower_limit="2.2" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 of study MENACWY-TT-100: hSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="4.1" upper_limit="15.2"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.2" upper_limit="7.6"/>
                    <measurement group_id="O3" value="40.3" lower_limit="23.9" upper_limit="68.1"/>
                    <measurement group_id="O4" value="7.3" lower_limit="2.7" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 of study MENACWY-TT-100: hSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="9.0" upper_limit="27.7"/>
                    <measurement group_id="O2" value="6.9" lower_limit="2.9" upper_limit="16.6"/>
                    <measurement group_id="O3" value="54.4" lower_limit="35.0" upper_limit="84.4"/>
                    <measurement group_id="O4" value="10.5" lower_limit="4.4" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 of study MENACWY-TT-100: hSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="7.3" upper_limit="18.6"/>
                    <measurement group_id="O2" value="8.7" lower_limit="3.5" upper_limit="21.5"/>
                    <measurement group_id="O3" value="43.7" lower_limit="27.5" upper_limit="69.5"/>
                    <measurement group_id="O4" value="8.8" lower_limit="3.4" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4 of study MENACWY-TT-100: hSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="4.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.3" upper_limit="15.0"/>
                    <measurement group_id="O3" value="35.5" lower_limit="21.5" upper_limit="58.8"/>
                    <measurement group_id="O4" value="6.2" lower_limit="2.5" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5 of study MENACWY-TT-100: hSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="5.3" upper_limit="14.2"/>
                    <measurement group_id="O2" value="8.5" lower_limit="2.8" upper_limit="25.7"/>
                    <measurement group_id="O3" value="36.8" lower_limit="22.4" upper_limit="60.7"/>
                    <measurement group_id="O4" value="13.9" lower_limit="4.2" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With rSBA Titers &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With rSBA Titers &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA: &gt;= 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="95.9" lower_limit="88.6" upper_limit="99.2"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;= 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;= 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY &gt;= 1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA: &gt;= 1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="95.9" lower_limit="88.6" upper_limit="99.2"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;= 1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;= 1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY &gt;= 1:28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in this study (MenACWY-TT-100) and had available assay results for the 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in this study (MenACWY-TT-100) and had available assay results for the 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5122.3" lower_limit="3725.6" upper_limit="7042.6"/>
                    <measurement group_id="O2" value="4871.0" lower_limit="2465.1" upper_limit="9624.9"/>
                    <measurement group_id="O3" value="4626.4" lower_limit="3040.6" upper_limit="7039.4"/>
                    <measurement group_id="O4" value="6414.2" lower_limit="3878.5" upper_limit="10607.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7163.5" lower_limit="5478.0" upper_limit="9367.7"/>
                    <measurement group_id="O2" value="5792.6" lower_limit="3630.6" upper_limit="9242.2"/>
                    <measurement group_id="O3" value="4020.0" lower_limit="3319.0" upper_limit="4869.1"/>
                    <measurement group_id="O4" value="15101.0" lower_limit="7099.3" upper_limit="32121.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25911.2" lower_limit="19119.7" upper_limit="35115.2"/>
                    <measurement group_id="O2" value="17970.4" lower_limit="11666.4" upper_limit="27680.7"/>
                    <measurement group_id="O3" value="27944.4" lower_limit="22213.8" upper_limit="35153.3"/>
                    <measurement group_id="O4" value="10462.5" lower_limit="3253.5" upper_limit="33645.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7660.5" lower_limit="5262.9" upper_limit="11150.3"/>
                    <measurement group_id="O2" value="6316.9" lower_limit="3223.8" upper_limit="12377.5"/>
                    <measurement group_id="O3" value="7529.7" lower_limit="5827.5" upper_limit="9729.2"/>
                    <measurement group_id="O4" value="6959.2" lower_limit="3636.7" upper_limit="13317.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: rSBA antibody titer &gt;= 1:32 one month after vaccination, and at least 4-fold increase in rSBA titers one month after vaccination.</description>
        <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in this study (MenACWY-TT-100), had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: rSBA antibody titer &gt;= 1:32 one month after vaccination, and at least 4-fold increase in rSBA titers one month after vaccination.</description>
          <population>All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in this study (MenACWY-TT-100), had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="80.1" upper_limit="96.4"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="87.7" lower_limit="77.9" upper_limit="94.2"/>
                    <measurement group_id="O4" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="70.5" upper_limit="90.8"/>
                    <measurement group_id="O2" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="75.7" lower_limit="64.3" upper_limit="84.9"/>
                    <measurement group_id="O4" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="88.2" lower_limit="63.6" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="86.5" upper_limit="99.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O3" value="93.2" lower_limit="84.9" upper_limit="97.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With hSBA Titers &gt;=1:4 and &gt;=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants: received primary vaccination in study MenACWY-TT-027, booster vaccination in study MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With hSBA Titers &gt;=1:4 and &gt;=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants: received primary vaccination in study MenACWY-TT-027, booster vaccination in study MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA: &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC: &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135: &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="75.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY: &gt;=1:4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.1" upper_limit="99.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenA: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="61.7" upper_limit="98.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="75.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY: &gt;=1:8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.1" upper_limit="99.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants: received primary vaccination in study MenACWY-TT-027, booster vaccination in study MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>All eligible participants: received primary vaccination in study MenACWY-TT-027, booster vaccination in study MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup titers cut off.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1534.2" lower_limit="1112.1" upper_limit="2116.6"/>
                    <measurement group_id="O2" value="90.0" lower_limit="35.7" upper_limit="227.1"/>
                    <measurement group_id="O3" value="1213.0" lower_limit="993.9" upper_limit="1480.5"/>
                    <measurement group_id="O4" value="211.1" lower_limit="130.9" upper_limit="340.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33959.8" lower_limit="23890.2" upper_limit="48273.5"/>
                    <measurement group_id="O2" value="42559.2" lower_limit="20106.2" upper_limit="90086.2"/>
                    <measurement group_id="O3" value="15543.5" lower_limit="11734.9" upper_limit="20588.3"/>
                    <measurement group_id="O4" value="44794.4" lower_limit="10111.6" upper_limit="198440.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11924.8" lower_limit="8715.6" upper_limit="16315.7"/>
                    <measurement group_id="O2" value="258.1" lower_limit="155.7" upper_limit="427.8"/>
                    <measurement group_id="O3" value="6965.2" lower_limit="5274.3" upper_limit="9198.3"/>
                    <measurement group_id="O4" value="199.6" lower_limit="101.0" upper_limit="394.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12154.3" lower_limit="9660.9" upper_limit="15291.1"/>
                    <measurement group_id="O2" value="407.8" lower_limit="129.9" upper_limit="1280.3"/>
                    <measurement group_id="O3" value="11127.4" lower_limit="8909.2" upper_limit="13898.0"/>
                    <measurement group_id="O4" value="453.9" lower_limit="214.6" upper_limit="959.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY. hSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: hSBA antibody titer &gt;= 1:8 one month after vaccination, and at least 4-fold increase in hSBA titers one month after vaccination.</description>
        <time_frame>1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)</time_frame>
        <population>All eligible participants: received primary vaccination in study MenACWY-TT-027, booster vaccination in study MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY. hSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: hSBA antibody titer &gt;= 1:8 one month after vaccination, and at least 4-fold increase in hSBA titers one month after vaccination.</description>
          <population>All eligible participants: received primary vaccination in study MenACWY-TT-027, booster vaccination in study MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. “N”: number of participants evaluable for this measure. “Number analyzed”: participants analyzed for specified serogroup.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.1" upper_limit="99.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="88.2" lower_limit="63.6" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" lower_limit="74.2" upper_limit="93.7"/>
                    <measurement group_id="O2" value="92.9" lower_limit="66.1" upper_limit="99.8"/>
                    <measurement group_id="O3" value="85.7" lower_limit="75.3" upper_limit="92.9"/>
                    <measurement group_id="O4" value="94.1" lower_limit="71.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O3" value="96.6" lower_limit="88.3" upper_limit="99.6"/>
                    <measurement group_id="O4" value="100.0" lower_limit="76.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="71.4" lower_limit="41.9" upper_limit="91.6"/>
                    <measurement group_id="O3" value="98.5" lower_limit="91.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="78.6" lower_limit="49.2" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs related to &quot;lack of vaccine efficacy&quot; were as judged by the investigator.</description>
        <time_frame>Through 5 years (6, 7, 8, 9 and 10 years post primary vaccination)</time_frame>
        <population>All the participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs related to &quot;lack of vaccine efficacy&quot; were as judged by the investigator.</description>
          <population>All the participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination</title>
        <description>Solicited general events: fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea and/or abdominal pain, headache (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe/prevented normal activity) and fever (&gt;=37.5°C for oral/axillary/tympanic route, &gt;=38.0°C for rectal route). Solicited local events: pain (0=none, 1=mild, not interfered/prevented normal activity, 2=moderate, painful when limb moved/interfered with normal activity, 3=severe, significant pain at rest/prevented normal activity), redness and swelling at injection site (record greatest surface diameter in millimeter (mm) as 0 to &lt;=20 mm, &gt;20 to &lt;=50 mm, &gt;50 mm). Participants may be represented in more than 1 category. Only categories with at least 1 participant reported. 'Medical advice' signifies medical advice received to resolve any event. 'Related'=relationship to study vaccine assessed by investigator.</description>
        <time_frame>Up to 4 days post booster vaccination</time_frame>
        <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage. “Number analyzed”: participants analyzed for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination</title>
          <description>Solicited general events: fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea and/or abdominal pain, headache (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe/prevented normal activity) and fever (&gt;=37.5°C for oral/axillary/tympanic route, &gt;=38.0°C for rectal route). Solicited local events: pain (0=none, 1=mild, not interfered/prevented normal activity, 2=moderate, painful when limb moved/interfered with normal activity, 3=severe, significant pain at rest/prevented normal activity), redness and swelling at injection site (record greatest surface diameter in millimeter (mm) as 0 to &lt;=20 mm, &gt;20 to &lt;=50 mm, &gt;50 mm). Participants may be represented in more than 1 category. Only categories with at least 1 participant reported. 'Medical advice' signifies medical advice received to resolve any event. 'Related'=relationship to study vaccine assessed by investigator.</description>
          <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage. “Number analyzed”: participants analyzed for specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7"/>
                    <measurement group_id="O2" value="56.3"/>
                    <measurement group_id="O3" value="59.5"/>
                    <measurement group_id="O4" value="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="40.5"/>
                    <measurement group_id="O4" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="16.2"/>
                    <measurement group_id="O4" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pain: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All redness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="43.8"/>
                    <measurement group_id="O3" value="36.5"/>
                    <measurement group_id="O4" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: 0 to &lt;=20 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="31.1"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: &gt;20 to &lt;=50 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: &gt;50 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="23.0"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: 0 to &lt;=20 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="16.2"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: &gt;20 to &lt;=50 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: &gt;50 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="29.7"/>
                    <measurement group_id="O4" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="16.2"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Related fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="29.7"/>
                    <measurement group_id="O4" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 3 Related</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Related</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 3 related</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All gastrointestinal event (GI)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="17.6"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="13.5"/>
                    <measurement group_id="O4" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Related</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="17.6"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Grade 3 related</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="18.9"/>
                    <measurement group_id="O4" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Related</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="24.3"/>
                    <measurement group_id="O4" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 3 related</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Medical advice</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination</title>
        <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Up to 31 days post booster vaccination</time_frame>
        <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination</title>
          <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="35.1"/>
                    <measurement group_id="O4" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination</title>
        <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Up to 6 months post booster vaccination</time_frame>
        <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination</title>
          <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination</title>
        <description>New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.</description>
        <time_frame>Up to 6 months post booster vaccination</time_frame>
        <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-TT Vaccine: Less Than (&lt;) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenCCRM (Meningitec) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-TT Vaccine: Greater Than or Equal to (&gt;=) 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
          <group group_id="O4">
            <title>MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years</title>
            <description>Persistence phase was followed up by booster phase. Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination</title>
          <description>New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.</description>
          <population>Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For persistence phase: Through 5 years (6, 7, 8, 9 and 10 years post primary vaccination); Booster phase: up to 6 months after booster vaccination</time_frame>
      <desc>Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Persistence Phase: MenACWY-TT Vaccine (Less Than [&lt;] 2 Years)</title>
          <description>Participants with &lt;2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long-term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027).</description>
        </group>
        <group group_id="E2">
          <title>Persistence Phase:MenCCRM (Meningitec) Vaccine(&lt;2 Years)</title>
          <description>Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long-term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027).</description>
        </group>
        <group group_id="E3">
          <title>Persistence Phase: MenACWY-TT Vaccine (&gt;=2 Years)</title>
          <description>Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long-term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027).</description>
        </group>
        <group group_id="E4">
          <title>Persistence Phase: MenPS (Mencevax ACWY) Vaccine (&lt; 2 Years)</title>
          <description>Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027).</description>
        </group>
        <group group_id="E5">
          <title>Booster Phase: MenACWY-TT Vaccine (Less Than 2 Years)</title>
          <description>Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long-term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027). Booster phase: Participants received a single 0.5 mL booster dose of MenACWY-TT intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months.</description>
        </group>
        <group group_id="E6">
          <title>Booster Phase: MenCCRM (Meningitec) Vaccine (&lt;2 Years)</title>
          <description>Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long-term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027). Booster phase: Participants received a single 0.5 mL booster dose of MenACWY-TT intramuscularly in this study, 10 years post primary vaccination, and were followed up for 6 months.</description>
        </group>
        <group group_id="E7">
          <title>Booster Phase: MenACWY-TT Vaccine (&gt;= 2 Years)</title>
          <description>Persistence phase: Participants with &gt;=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long-term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027). Booster phase: Participants received a single 0.5 mL booster dose of MenACWY-TT in this study, 10 years post primary vaccination, and were followed up for 6 months.</description>
        </group>
        <group group_id="E8">
          <title>Booster Phase: MenPS (Mencevax ACWY) Vaccine (&lt;2 Years)</title>
          <description>Persistence phase: Participants with &lt;2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study they were evaluated for long term persistence for a maximum duration of 5 years (6, 7, 8, 9 and 10 years post primary vaccination in MENACWY-TT-027). Booster phase: Participants received a single 0.5 mL booster dose of MenACWY-TT in this study, 10 years post primary vaccination, and were followed up for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="65" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site erythema (redness)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site pain (pain at injection site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="44" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site swelling (swelling)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

